The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J06 | Immune sera and immunoglobulins | |
| 3 | J06B | Immunoglobulins | |
| 4 | J06BC | Antibacterial monoclonal antibodies |
| Code | Title | |
|---|---|---|
| J06BC01 | Nebacumab | |
| J06BC02 | ||
| J06BC03 | ||
| J06BC04 |
| Active Ingredient | Description | |
|---|---|---|
| Bezlotoxumab |
Bezlotoxumab is a human monoclonal antitoxin antibody that binds with high affinity to C. difficile toxin B and neutralizes its activity. Bezlotoxumab prevents CDI recurrence by providing passive immunity against toxin produced by the outgrowth of persistent or newly-acquired C. difficile spores. |
|
| Obiltoxaximab |
Obiltoxaximab is a monoclonal antibody that binds the protective antigen (PA) of B. anthracis. Obiltoxaximab inhibits the binding of PA to its cellular receptors, preventing the intracellular entry of the anthrax lethal factor and oedema factor, the enzymatic toxin components responsible for the pathogenic effects of anthrax toxin. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| NYXTHRACIS Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ZINPLAVA Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
